HeartSciences (HSCS) Expected to Release Quarterly Earnings on Thursday

Posted by Latisha Jones on Sep 8th, 2026

HeartSciences (NASDAQ:HSCS – Get Free Report) is anticipated to issue its Q1 2027 results before the market opens on Thursday, September 10th. Analysts expect HeartSciences to post earnings of ($0.72) per share and revenue of $0.10 million for the quarter. Parties can check the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Friday, September 18, 2026 at 4:00 PM ET.

HeartSciences (NASDAQ:HSCS – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). On average, analysts expect HeartSciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

HeartSciences Trading Up 9.4%

Shares of NASDAQ HSCS opened at $4.08 on Wednesday. The business has a 50-day moving average of $2.62 and a 200-day moving average of $2.37. The firm has a market capitalization of $15.91 million, a price-to-earnings ratio of -1.04 and a beta of 1.85. HeartSciences has a 12 month low of $1.63 and a 12 month high of $4.35.

Institutional Trading of HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new position in HeartSciences Inc. (NASDAQ:HSCS – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Check Out Our Latest Stock Report on HSCS

HeartSciences Company Profile

(Get Free Report)

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.